aminotransferase


Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.
Related to aminotransferase: alanine aminotransferase, aspartate aminotransferase

aminotransferase

[ə‚mē·nō′tranz·fə‚rās]
(biochemistry)
References in periodicals archive ?
Plasma enzyme activities of alanine aminotransferase and aspartate aminotransferase were determined using commercial kits (Zhongsheng Bio-Technology and Science Inc.
5 Direct bilirubin (mg/dL) -- >10 >10 Aspartate aminotransferase (IU/dL) 64 45 91 Alanine aminotransferase (IU/dL) 15 24 31 Day 2 Day 4 Day 7 Transfusion White blood cell count (K/uL) 13.
5 mg/dL CO2 31 mmol/L 18-27 mmol/L Aspartate aminotransferase 3669 U/L 15-40 U/L Alanine aminotransferase 676 U/L 27-42 U/L Alkaline phosphatase 150 U/L 92-336 U/L 7-Glutamyl transpeptidase 10 U/L 14-35 U/L
0 Alkaline phosphatase, U/L 58 60 Aspartate aminotransferase, U/L 43 37 Alanine aminotransferase, U/L 92 102 Total bilirubin, mg/dL 0.
Biochemical response to therapy was determined by comparing aminotransferase levels in plasma samples before treatment and at 24 weeks into therapy.
Aminotransferase levels remained in normal range while on niacin, although slightly higher.
Laboratory data included test results for bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), all viral hepatitis serologic assays, rheumatoid factor, and human immunodeficiency virus antibody at the time of diagnosis.
Results showed that in the licorice group there was a reduction in alanine aminotransferase (ALT) from 64.
It act by selectively inhibiting the synthesis of purine nucleotides (adenine) and reducing DNA synthesis of a variety of immunologic and other specialized cells, including hepatocytes due to oral administration of AZA increase liver enzymes level as alkaline phosphatase (ALP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Aspartate aminotransferase, calcium, creatine kinase, lactate dehydrogenase, total protein, triglycerides, and uric acid in plasma were determined by a commercial laboratory (Vet Pro Labs, Tulsa, Oklahoma).
However, one of the two patients treated with the high dose experienced a transient, asymptomatic increase in serum aspartate and alanine aminotransferase levels caused by AAV8-capsid-specific T cells in the peripheral blood, and the other patient in the high-dose group experienced a slight increase (though still below the upper limit of normal) in liver enzyme levels.
Catalyst has two products in development, and is currently evaluating its lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor), for the treatment of cocaine addiction.